Arbutus Biopharma (ABUS) Projected to Post Earnings on Thursday

Key Points

• Arbutus Biopharma (NASDAQ:ABUS) is expected to release its Q2 2025 earnings on Thursday, August 7th, with analysts predicting a loss of ($0.02) per share.
• The company reported a loss of ($0.13) per share in its previous earnings announcement, missing estimates by ($0.04).
• Goldman Sachs Group Inc. significantly increased its stake in Arbutus Biopharma by 290.3%, now owning 1.08% of the company's shares.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $2.21 million for the quarter.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.04). Arbutus Biopharma had a negative net margin of 1,196.64% and a negative return on equity of 75.51%. The company had revenue of $1.76 million for the quarter, compared to analysts' expectations of $2.54 million. On average, analysts expect Arbutus Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Arbutus Biopharma Trading Down 0.3%

NASDAQ:ABUS traded down $0.01 during midday trading on Friday, hitting $3.27. 553,477 shares of the company traded hands, compared to its average volume of 662,202. The firm's fifty day moving average is $3.32 and its 200-day moving average is $3.30. Arbutus Biopharma has a 12-month low of $2.70 and a 12-month high of $4.72. The firm has a market capitalization of $626.30 million, a P/E ratio of -7.98 and a beta of 0.86. The company has a current ratio of 6.01, a quick ratio of 6.01 and a debt-to-equity ratio of 0.04.

Hedge Funds Weigh In On Arbutus Biopharma

A hedge fund recently raised its stake in Arbutus Biopharma stock. Goldman Sachs Group Inc. raised its holdings in Arbutus Biopharma Corporation (NASDAQ:ABUS - Free Report) by 290.3% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,075,948 shares of the biopharmaceutical company's stock after acquiring an additional 1,544,070 shares during the quarter. Goldman Sachs Group Inc. owned approximately 1.08% of Arbutus Biopharma worth $7,245,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 43.79% of the company's stock.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.